脂药物在急性冠心症及脑中风的使用.pptVIP

下载本文档

0
0
约3.58千字
约 16页
2017-12-15 发布于湖北
举报
版权申诉

脂药物在急性冠心症及脑中风的使用.ppt

1、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

脂药物在急性冠心症及脑中风的使用

Statin in Acute Coronary Syndrome Statin in Acute Ischemic Stroke and Transient Ischemic Attack Recommendations from the American Heart Association (AHA)/American Stroke Association (ASA) suggest that statin therapy should be used in the vast majority of patients with a history of ischemic stroke or TIA. However, it remains unclear as to how soon statin should be initiated after acute ischemic stroke. Statin initiation during hospitalization for first ischemic stroke of atherosclerotic origin is probably justified based on ACS trials Taiwan Stroke Registry Taiwan Stroke Registry, launched on May 1, 2006 and engaging 37 hospitals around Taiwan, prospectively collected data of patients who developed acute stroke or TIA and were hospitalized within 10 days after onset. All patients were followed up for at least 6 months after discharge. * * Use of Lipid-lowering Agent in Acute Coronary Syndrome and Ischemic Stroke in Taiwan Yi-Heng Li, MD, PhD Department of Internal Medicine College of Medicine National Cheng Kung University 成功大學醫學院內科李貽恆 Liao JK. Am J Cardiol. 2005;96(suppl 1):24F-33F. MMPs = matrix metalloproteinases ? Platelet activation ? Coagulation ? Endothelial progenitor cells ? Effects on collagen ? MMPs ? AT1 receptor ? VSMC proliferation ? Endothelin ? Macrophages ? Inflammation ? Immunomodulation ? Endothelial function ? Reactive oxygen species ? NO bioactivity Pleiotropic effects of statins Statins MIRACL Study Relative risk = 0.84P = .048 95% CI 0.701-0.999 Atorvastatin Placebo 0 5 10 15 0 4 8 12 16 Time Since Randomization (weeks) Cumulative Incidence (%) Time to first occurrence of: Death (any cause) Nonfatal MI Resuscitated cardiac arrest Worsening angina with new objective evidence and urgent rehospitalization 17.4% 14.8% Primary Efficacy Measure Schwartz GG, et al. JAMA. 2001;285:1711-1718. Very early benefit Statin Use in ACS: NCKUH Experience Inclusion criteria: - January 2000 ~ December 2004 - patients admitted to the NCKUH with